153 related articles for article (PubMed ID: 34569452)
1. Screening of
Chandel S; Singh R; Gautam A; Ravichandiran V
J Biomol Struct Dyn; 2022; 40(23):12827-12840. PubMed ID: 34569452
[TBL] [Abstract][Full Text] [Related]
2. Screening of potential drug for Alzheimer's disease: a computational study with GSK-3 β inhibition through virtual screening, docking, and molecular dynamics simulation.
Elangovan ND; Dhanabalan AK; Gunasekaran K; Kandimalla R; Sankarganesh D
J Biomol Struct Dyn; 2021 Nov; 39(18):7065-7079. PubMed ID: 32779973
[TBL] [Abstract][Full Text] [Related]
3. Prediction of binding affinity of 1,2-diphenyline ketone analogues at adenosine triphosphate binding site of glycogen synthase kinase-3β: a molecular docking and dynamic simulation study.
Dinakar S; Gurubarath M; Dhananjayan K
J Biomol Struct Dyn; 2023 Jul; 41(11):4847-4862. PubMed ID: 35543239
[TBL] [Abstract][Full Text] [Related]
4. Docking, molecular dynamics, binding energy-MM-PBSA studies of naphthofuran derivatives to identify potential dual inhibitors against BACE-1 and GSK-3β.
Kumar A; Srivastava G; Negi AS; Sharma A
J Biomol Struct Dyn; 2019 Feb; 37(2):275-290. PubMed ID: 29310523
[TBL] [Abstract][Full Text] [Related]
5. (Z)-2-(3-Chlorobenzylidene)-3,4-dihydro-N-(2-methoxyethyl)-3-oxo-2H-benzo[b][1,4]oxazine-6-carboxamide as GSK-3β inhibitor: Identification by virtual screening and its validation in enzyme- and cell-based assay.
Joshi P; Gupta M; Vishwakarma RA; Kumar A; Bharate SB
Chem Biol Drug Des; 2017 Jun; 89(6):964-971. PubMed ID: 27896926
[TBL] [Abstract][Full Text] [Related]
6. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
[TBL] [Abstract][Full Text] [Related]
7. Design, Bio-evaluation and Molecular Dynamics Simulation of Novel GSK-3β Inhibitors.
Lyu W; Li Q; Li Q; Chen Y; Wang Y; Tang T; Feng F; Chi H; Li Y; Liu W; Sun H
Mol Inform; 2021 Dec; 40(12):e2060031. PubMed ID: 34323388
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel harmine derivatives as GSK-3β/DYRK1A dual inhibitors for Alzheimer's disease treatment.
Qiu J; Feng X; Chen H; Liu W; Liu W; Wu L; Gao X; Liu Y; Huang Y; Gong H; Qi Y; Xu Z; Zhao Q
Arch Pharm (Weinheim); 2024 Feb; 357(2):e2300404. PubMed ID: 38010470
[TBL] [Abstract][Full Text] [Related]
9. E-pharmacophore-based virtual screening to identify GSK-3β inhibitors.
Natarajan P; Priyadarshini V; Pradhan D; Manne M; Swargam S; Kanipakam H; Bhuma V; Amineni U
J Recept Signal Transduct Res; 2016 Oct; 36(5):445-58. PubMed ID: 27305963
[TBL] [Abstract][Full Text] [Related]
10. Biological evaluation and energetic analyses of novel GSK-3β inhibitors.
Zhang D; Liu L; Pang L; Jin Q; Ke K; Hu M; Yang J; Ma W; Xie H; Chen X
J Cell Biochem; 2018 Apr; 119(4):3510-3518. PubMed ID: 29144001
[TBL] [Abstract][Full Text] [Related]
11. Investigation of naphthofuran moiety as potential dual inhibitor against BACE-1 and GSK-3β: molecular dynamics simulations, binding energy, and network analysis to identify first-in-class dual inhibitors against Alzheimer's disease.
Kumar A; Srivastava G; Srivastava S; Verma S; Negi AS; Sharma A
J Mol Model; 2017 Aug; 23(8):239. PubMed ID: 28741112
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel α-carboline derivatives as glycogen synthase kinase-3β inhibitors for the treatment of Alzheimer's disease.
Chen H; Yu C; Liu W; Zhu C; Jiang X; Xu C; Liu W; Huang Y; Xu Z; Zhao Q
Arch Pharm (Weinheim); 2022 Oct; 355(10):e2200156. PubMed ID: 35836098
[TBL] [Abstract][Full Text] [Related]
13. Receptor-based pharmacophore modeling, virtual screening, and molecular docking studies for the discovery of novel GSK-3β inhibitors.
El Kerdawy AM; Osman AA; Zaater MA
J Mol Model; 2019 May; 25(6):171. PubMed ID: 31129879
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein E and beta-amyloid (1-42) regulation of glycogen synthase kinase-3beta.
Cedazo-Mínguez A; Popescu BO; Blanco-Millán JM; Akterin S; Pei JJ; Winblad B; Cowburn RF
J Neurochem; 2003 Dec; 87(5):1152-64. PubMed ID: 14622095
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of glycogen synthase kinase-3beta contributes to brain-derived neutrophic factor/TrkB-induced resistance to chemotherapy in neuroblastoma cells.
Li Z; Tan F; Thiele CJ
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3113-21. PubMed ID: 18089706
[TBL] [Abstract][Full Text] [Related]
16. Molecular Docking and Dynamics Simulation of Natural Phenolic Compounds with GSK-3β: A Putative Target to Combat Mortality in Patients with COVID-19.
Khamverdi Z; Mohamadi Z; Taherkhani A
Recent Adv Inflamm Allergy Drug Discov; 2022; 15(1):16-34. PubMed ID: 35253634
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of N-alkyl or aryl substituted isoindigo derivatives as potential dual cyclin-dependent kinase 2 (CDK2)/glycogen synthase kinase 3β (GSK-3β) phosphorylation inhibitors.
Zhao P; Li Y; Gao G; Wang S; Yan Y; Zhan X; Liu Z; Mao Z; Chen S; Wang L
Eur J Med Chem; 2014 Oct; 86():165-74. PubMed ID: 25151579
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of zinc-induced phosphorylation of p70 S6 kinase and glycogen synthase kinase 3beta in SH-SY5Y neuroblastoma cells.
An WL; Bjorkdahl C; Liu R; Cowburn RF; Winblad B; Pei JJ
J Neurochem; 2005 Mar; 92(5):1104-15. PubMed ID: 15715661
[TBL] [Abstract][Full Text] [Related]
19. Binding of BIS like and other ligands with the GSK-3β kinase: a combined docking and MM-PBSA study.
Jena NR
J Mol Model; 2012 Feb; 18(2):631-44. PubMed ID: 21559963
[TBL] [Abstract][Full Text] [Related]
20. Membrane depolarization induces the undulating phosphorylation/dephosphorylation of glycogen synthase kinase 3beta, and this dephosphorylation involves protein phosphatases 2A and 2B in SH-SY5Y human neuroblastoma cells.
Lee YI; Seo M; Kim Y; Kim SY; Kang UG; Kim YS; Juhnn YS
J Biol Chem; 2005 Jun; 280(23):22044-52. PubMed ID: 15799972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]